REPORT ID 8924

Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size, Status and Forecast 2022

Publish Date
10-Nov-17
Pages
98
Format
Electronic (PDF)

This report studies the global Autologous Matrix-Induced Chondrogenesis (AMIC) market, analyzes and researches the Autologous Matrix-Induced Chondrogenesis (AMIC) development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like
    Anika Therapeutics, Inc.
    Arthro-Kinetics
    B. Braun Melsungen AG
    BioTissue AG
    CartiHeal
    Geistlich Pharma AG
    JRI Orthopaedics Ltd.
    Matricel GmbH
    Smith & Nephew plc
    Zimmer Biomet Holdings

Market segment by Regions/Countries, this report covers
    United States
    EU
    Japan
    China
    India
    Southeast Asia

Market segment by Type, the product can be split into
    Hyaluronic Acid
    Collagen
    Polyethylene glycol (PEG)
    polylactic-co-glycolic acid (PGLA)
    Others

Market segment by Application, Autologous Matrix-Induced Chondrogenesis (AMIC) can be split into
    Knee Cartilage Repair
    Hip Cartilage Repair
    Elbow Cartilage Repair
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.


 
			   
Table of Contents

Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size, Status and Forecast 2022
1 Industry Overview of Autologous Matrix-Induced Chondrogenesis (AMIC)
    1.1  Autologous Matrix-Induced Chondrogenesis (AMIC) Market Overview
        1.1.1 Autologous Matrix-Induced Chondrogenesis (AMIC) Product Scope
        1.1.2 Market Status and Outlook
    1.2 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Analysis by Regions
        1.2.1 United States
        1.2.2 EU
        1.2.3 Japan
        1.2.4 China
        1.2.5 India
        1.2.6 Southeast Asia
    1.3 Autologous Matrix-Induced Chondrogenesis (AMIC) Market by Type
        1.3.1 Hyaluronic Acid
        1.3.2 Collagen
        1.3.3 Polyethylene glycol (PEG)
        1.3.4 polylactic-co-glycolic acid (PGLA)
        1.3.5 Others
    1.4 Autologous Matrix-Induced Chondrogenesis (AMIC) Market by End Users/Application
        1.4.1 Knee Cartilage Repair
        1.4.2 Hip Cartilage Repair
        1.4.3 Elbow Cartilage Repair
        1.4.4 Others

2 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Competition Analysis by Players
    2.1 Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size (Value) by Players (2016 and 2017)
    2.2 Competitive Status and Trend
        2.2.1 Market Concentration Rate
        2.2.2 Product/Service Differences
        2.2.3 New Entrants
        2.2.4 The Technology Trends in Future

3 Company (Top Players) Profiles
    3.1 Anika Therapeutics, Inc.
        3.1.1 Company Profile
        3.1.2 Main Business/Business Overview
        3.1.3 Products, Services and Solutions
        3.1.4 Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (Value) (2012-2017)
        3.1.5 Recent Developments
    3.2 Arthro-Kinetics
        3.2.1 Company Profile
        3.2.2 Main Business/Business Overview
        3.2.3 Products, Services and Solutions
        3.2.4 Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (Value) (2012-2017)
        3.2.5 Recent Developments
    3.3 B. Braun Melsungen AG
        3.3.1 Company Profile
        3.3.2 Main Business/Business Overview
        3.3.3 Products, Services and Solutions
        3.3.4 Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (Value) (2012-2017)
        3.3.5 Recent Developments
    3.4 BioTissue AG
        3.4.1 Company Profile
        3.4.2 Main Business/Business Overview
        3.4.3 Products, Services and Solutions
        3.4.4 Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (Value) (2012-2017)
        3.4.5 Recent Developments
    3.5 CartiHeal
        3.5.1 Company Profile
        3.5.2 Main Business/Business Overview
        3.5.3 Products, Services and Solutions
        3.5.4 Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (Value) (2012-2017)
        3.5.5 Recent Developments
    3.6 Geistlich Pharma AG
        3.6.1 Company Profile
        3.6.2 Main Business/Business Overview
        3.6.3 Products, Services and Solutions
        3.6.4 Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (Value) (2012-2017)
        3.6.5 Recent Developments
    3.7 JRI Orthopaedics Ltd.
        3.7.1 Company Profile
        3.7.2 Main Business/Business Overview
        3.7.3 Products, Services and Solutions
        3.7.4 Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (Value) (2012-2017)
        3.7.5 Recent Developments
    3.8 Matricel GmbH
        3.8.1 Company Profile
        3.8.2 Main Business/Business Overview
        3.8.3 Products, Services and Solutions
        3.8.4 Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (Value) (2012-2017)
        3.8.5 Recent Developments
    3.9 Smith & Nephew plc
        3.9.1 Company Profile
        3.9.2 Main Business/Business Overview
        3.9.3 Products, Services and Solutions
        3.9.4 Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (Value) (2012-2017)
        3.9.5 Recent Developments
    3.10 Zimmer Biomet Holdings
        3.10.1 Company Profile
        3.10.2 Main Business/Business Overview
        3.10.3 Products, Services and Solutions
        3.10.4 Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (Value) (2012-2017)
        3.10.5 Recent Developments

4 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Type and Application (2012-2017)
    4.1 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Type (2012-2017)
    4.2 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Application (2012-2017)
    4.3 Potential Application of Autologous Matrix-Induced Chondrogenesis (AMIC) in Future
    4.4 Top Consumer/End Users of Autologous Matrix-Induced Chondrogenesis (AMIC)

5 United States Autologous Matrix-Induced Chondrogenesis (AMIC) Development Status and Outlook
    5.1 United States Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size (2012-2017)
    5.2 United States Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Market Share by Players (2016 and 2017)

6 EU Autologous Matrix-Induced Chondrogenesis (AMIC) Development Status and Outlook
    6.1 EU Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size (2012-2017)
    6.2 EU Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Market Share by Players (2016 and 2017)

7 Japan Autologous Matrix-Induced Chondrogenesis (AMIC) Development Status and Outlook
    7.1 Japan Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size (2012-2017)
    7.2 Japan Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Market Share by Players (2016 and 2017)

8 China Autologous Matrix-Induced Chondrogenesis (AMIC) Development Status and Outlook
    8.1 China Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size (2012-2017)
    8.2 China Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Market Share by Players (2016 and 2017)

9 India Autologous Matrix-Induced Chondrogenesis (AMIC) Development Status and Outlook
    9.1 India Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size (2012-2017)
    9.2 India Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Market Share by Players (2016 and 2017)

10 Southeast Asia Autologous Matrix-Induced Chondrogenesis (AMIC) Development Status and Outlook
    10.1 Southeast Asia Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size (2012-2017)
    10.2 Southeast Asia Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Market Share by Players (2016 and 2017)

11 Market Forecast by Regions, Type and Application (2017-2022)
    11.1 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size (Value) by Regions (2017-2022)
        11.1.1 United States Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2017-2022)
        11.1.2 EU Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2017-2022)
        11.1.3 Japan Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2017-2022)
        11.1.4 China Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2017-2022)
        11.1.5 India Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2017-2022)
        11.1.6 Southeast Asia Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2017-2022)
    11.2 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size (Value) by Type (2017-2022)
    11.3 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Application (2017-2022)

12 Autologous Matrix-Induced Chondrogenesis (AMIC) Market Dynamics
    12.1 Autologous Matrix-Induced Chondrogenesis (AMIC) Market Opportunities
    12.2 Autologous Matrix-Induced Chondrogenesis (AMIC) Challenge and Risk
        12.2.1 Competition from Opponents
        12.2.2 Downside Risks of Economy
    12.3 Autologous Matrix-Induced Chondrogenesis (AMIC) Market Constraints and Threat
        12.3.1 Threat from Substitute
        12.3.2 Government Policy
        12.3.3 Technology Risks
    12.4 Autologous Matrix-Induced Chondrogenesis (AMIC) Market Driving Force
        12.4.1 Growing Demand from Emerging Markets
        12.4.2 Potential Application

13 Market Effect Factors Analysis
    13.1 Technology Progress/Risk
        13.1.1 Substitutes
        13.1.2 Technology Progress in Related Industry
    13.2 Consumer Needs Trend/Customer Preference
    13.3 External Environmental Change
        13.3.1 Economic Fluctuations
        13.3.2 Other Risk Factors

14 Research Finding/Conclusion

15 Appendix
    Methodology
    Analyst Introduction
    Data Source